Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Other HBV / HDV (Hepcludex / Hepsera by Year
Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) — U.S. sales ($M) ($M)
Gilead Sciences Other HBV / HDV (Hepcludex / Hepsera: $0M in FY2023. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 0 | -100.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 2 | -80.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 10 | +400.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 2 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other HBV / HDV (Hepcludex / Hepsera ($M), annual FY2019–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hbv-other-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.